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The prevalence of antibiotic resistance has resulted in the need for new approaches to be developed to combat previously easily treat-
able infections.Themain aimof thisworkwas to establish the potential of the synthetic𝛼-diimine chromium(III) and ruthenium(II)
complexes (where the 𝛼-diimine ligands are bpy = 2,2-bipyridine, phen = 1,10-phenanthroline, and dppz = dipyrido[3,2-a:2󸀠,3󸀠-
c]-phenazine) like [Cr(phen)
3
]3+, [Cr(phen)
2
(dppz)]3+, [Ru(phen)
3
]2+, and [Ru(bpy)
3
]2+ as antibacterial agents by generating
oxidative stress. The [Cr(phen)
3
]3+ and [Cr(phen)
2
(dppz)]3+ complexes showed activity against Gram positive and Gram negative
bacteria with minimum inhibitory concentrations (MICs) ranging from 0.125𝜇g/mL to 1 𝜇g/mL, while [Ru(phen)
3
]2+ and
[Ru(bpy)
3
]2+ do not exhibit antimicrobial activity against the two bacterial genera studied at the concentration range used. When
ciprofloxacin was combined with [Cr(phen)
3
]3+ for the inhibition of Staphylococcus aureus and Escherichia coli, an important
synergistic effect was observed, FIC 0.066 for S. aureus and FIC 0.064 for E. coli.Thework described here shows that chromium(III)
complexes are bactericidal for S. aureus and E. coli. Our results indicate that 𝛼-diimine chromium(III) complexesmay be interesting
to open new paths for metallodrug chemotherapy against different bacterial genera since some of these complexes have been found
to exhibit remarkable antibacterial activities.
1. Introduction
Since their discovery, antibiotics have played an important
role in health care. However, the increasing emergence of
antibiotic resistance among a variety of microbial pathogens
stimulates intensive research efforts with the aim of identify-
ing alternative therapeutic approaches [1].
The chemistry of metallic complexes with heterocyclic
ligands has attracted the interest of both inorganic and bioin-
organic chemists in recent years, and the field of coordination
chemistry of metallic complexes has undergone a remarkable
growth during the past few decades and became a growing
class of research [2]. This enormous growth is attributed
to the synthesis of a large number and variety of synthetic
ligands (chelates) which behave as coordinating agents for
metal ions [3]. It is known that 2,2󸀠-bipyridine and 1,10-phe-
nanthroline chelators act as potential antitumor agents [4, 5]
and several metal chelates possess antibacterial, antifungal,
antiviral and anticancer activities. However, in several cases,
it has been found that metal chelates havemore antimicrobial
activity than the chelating agents themselves [6].
The study of the chromium complexes in coordination
chemistry is of great significance due to their various appli-
cations in biological processes. In vitro studies have demon-
strated that chromium in the proper ligand environment can
lead to DNA damage, plasmid cleavage, and protein cleavage
[7–9]. Some reports showed chromium complexes as the
cause of oxidation of DNA by binding with guanine [10, 11].
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Additionally, octahedral transition metal complexes contain-
ing three bipyridine or phenanthroline ligands have been
shown to be groove binders or possible partial DNA interca-
lators [12, 13], whereas some chromium(III) Schiff base com-
plexes prefer nonintercalative mode of binding to DNA [7].
On the other hand, it has been reported that the bovine serum
albumin (BSA) protein damage brought about by chro-
mium(III) complexes depends on the nature of the coordi-
nated ligand and the nature of the metal complex [9].
As part of an ongoing program to investigate the interac-
tion of transition metal with double-helical DNA, we found
that the 𝛼-diimine chromium(III) complexes are associated
with DNA by noncovalent interactions. The chromium(III)
complexes are capable of producing plasmidic DNA photo-
damage with high efficiency of photocleavage [14–16]. This
leads to consider these complexes as attractive photosensitiz-
ing agents to be used in photodynamic therapy (PDT).
On the other hand, coordination complexes of transition
metals have been widely studied due to their antimicrobial
properties [17–21]. The importance of chromium as an envi-
ronmental pollutant and its involvement in the toxicity in
animals and plants have made the study of the interactions
of derivatives of this metal with microbial cells in a fertile
field for both basic research and applied science [22]. In this
sense, it was reported that chromium(III) complexes contain-
ing oxalohydrazide and quinoxaline as ligands would have
microbiological activity [23, 24], reducing virulence and
antibiotic resistance, causing loss of the plasmid of Shigella
dysenteriae that contains genes encoding virulence factors
responsible for this organism’s ability to penetrate and multi-
ply into the cells [25]. Furthermore, it has been reported that
chromium(III) complexes containing amino acids as ligands
have antibacterial and antifungal activities [26], and the
authors suggest that the mechanism of antibacterial activity
of this complexes would be due to oxidative DNA damage.
Emerging reports on the biotoxicity of chromium(III) com-
plexes have emphasized the effects of the coordinated ligand
on metal activity [27].
Diverse substances affect the reactive oxygen species
(ROS) generation in bacterial cells, and they have the capacity
to undergo redox cycling, resulting in the generation of super-
oxide anion (O
2
−) and hydrogen peroxide (H
2
O
2
). We have
described that several antibiotics induce oxidative stress in
bacteria, among them ciprofloxacin [28–31].
The aim of this investigation was to study the potential
antimicrobial activity of certain chromium(III) and ruthe-
nium(II) complexes and their combination with ciprofloxa-
cin, and this will provide an understanding of the potential
enhancing of the activity of this antibiotic by generating oxi-
dative stress in two different bacterial genera.
2. Materials and Methods
2.1. Reagents. 1,10-Phenanthroline (phen), tris(1,10-phenan-
throline)ruthenium(II) chloride ([Ru(phen)
3
]Cl
2
), and tris(2,
2󸀠-bipyridine)ruthenium(II) chloride ([Ru(bpy)
3
]Cl
2
) were
purchased from Sigma and used as received. Tris-phenan-
throline chromium (III) perchlorate ([Cr(phen)
3
](ClO
4
)
3
)
was obtained from previous studies, synthesized according
to the literature, and recrystallized at least three times. The
ligand dppz was synthesized and purified according to the lit-
erature [32]. Bis(1,10-phenanthroline)dipyrido[3,2-a:2󸀠,3󸀠-c]-
phenazine chromium(III) triflate ([Cr(phen)
2
(dppz)](CF
3
SO
3
)
3
)
was synthesized with slight modifications according to a
previously reported procedure [33]. The stock solutions
[Cr(phen)
3
]3+ and [Cr(phen)
2
(dppz)]3+ were prepared in
phosphate buffer saline (PBS, pH 7.4), and the concentra-
tion of chromium complexes was calculated using molar
extinction coefficients of 𝜀
354
= 4200M−1 cm−1 and 𝜀
360
= 13900M−1 cm−1, respectively [33]. CrCl
3
⋅ 6H
2
O (Fluka,
purity 98%) was used without further purification. Millipore
Milli Q water was used for preparing buffer solutions. All
other chemical reagents were of analytical grade.
2.2. Minimal Inhibitory Concentration (MIC) Determination.
The antimicrobial activity of the compounds in Staphylococ-
cus aureus ATCC 29213 and Escherichia coli ATCC 25922
was evaluated by using the standard tube dilution method on
Mueller Hinton broth (MH, Britania). Strains coming from
cultures of 24 h in Mueller Hinton medium were diluted to
106 colony-forming units (CFU) per mL and incubated for
10min at 37∘C; the compounds were then added at different
concentrations (from 0.004 to 2𝜇g/mL). Bacterial growth
was observed at 18 h of incubation, following the indications
of the Clinical and Laboratory Standards Institute [34]. For
comparison, chromium(III) and ruthenium(II) complexes
were tested. In addition, the MICs of the ligands (bpy, phen
and dppz) and CrCl
3
⋅ 6H
2
O were calculated. Serial dilutions
in phosphate buffer solution (PBS), pH 7.4 of the complexes
(0.5mL), were made. The concentrations of the compounds
were ranged from 0.004 to 2 𝜇g/mL. Dilutions of a standard
antibiotic (from 0.008 to 4 𝜇g/mL of ciprofloxacin) were also
prepared in the same manner. An overnight culture of each
microorganism was diluted to achieve a cell density in the
range from 105 to 107 CFU/mL. The cell suspension (0.5mL)
was inoculated into each tube to give a total volume of 1mL.
The lowest concentration of each complex that prevented
bacterial growth was considered to be the MIC. Inoculated
complexes-free broths were used as negative controls. Viable
bacterial counts were obtained for control samples by plating
serial dilutions on MH agar plates, followed by aerobic incu-
bation at 37∘C for 18 h for E. coli and S. aureus.
2.3. Time-Kill Study. The bactericidal activity was explored
by the time-kill method according to CLSI [34]. Kill curves
were constructed by plotting the CFU/mL surviving at each
time point in the presence and absence of [Cr(phen)
3
]3+ in
E. coli ATCC 25922 and S. aureus ATCC 29213.
2.4. Checkerboard Assay. The interactions between the chro-
mium(III) complexes and ciprofloxacin were evaluated by
the checkerboard method [35]. Bacterial growth inhibition
resulting from the interactions was determined by the
microdilution test. The concentrations of each tested agent
used in the combinations corresponded to serial 2-fold
dilutions from their MIC values. The fractional inhibitory
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Figure 1: Time-kill kinetics of [Cr(phen)
3
]3+ complex at minimum inhibitory concentration (MIC) (Δ) and control (∙). (a) Staphylococcus
aureus ATCC 29213. (b) Escherichia coli ATCC 25922.
concentration (FIC) was calculated using the MIC from the
checkerboard assay and the MIC of each compound alone,
obtained in parallel in the same assay, according to the follow-
ing formula: FIC = MIC of antimicrobial agent in combina-
tion/MIC of antimicrobial agent alone. Then, the synergistic
effect was evaluated by calculating the FICindex (FICI) for
each combination, by adding the individual FIC values. An
FICI of 0.5 indicated synergy for the combination. When it
fell between 0.5 and 1, it was defined as an additive effect,
and between 1.0 and 4.0 it was classified as “no interaction.”
Finally, an FICI> 4.0 indicated antagonismbetween the com-
ponents in the combination.
2.5. Determination of ROS by Chemiluminescence (CL) Assay.
Oxidative stress of S. aureus ATCC 29213 and E. coli ATCC
25922 was investigated in a BioOrbit luminometer. Bacteria
were cultured in triptein soy broth (TSB) at 37∘C for 24 h.
0.1mL of bacterial suspension was incubated with 0.1mL
of 75 𝜇g/mL lucigenin (bis-N-methylacridinium dinitrate),
0.1mL of PBS, pH 7.2 and 0.1mL of ciprofloxacin (from
0.033 to 4 𝜇g/mL) and 0.1mL of [Cr(phen)
3
]3+ (from 0.033 to
4 𝜇g/mL). Finally, the reaction was triggered with 0.1mL of
dimethylsulfoxide (DMSO) in the moment of determination.
Controls of basal production of ROS were performed with
bacteria in absence of antibiotic. The light emitted by ROS
was expressed as relative light unities (RLU) at different times
in seconds.
3. Results
3.1. Minimal Inhibitory Concentration (MIC) Determination.
Four chemically macrocyclic complexes and their ligands
(Figure 1) were screened for their in vitro antibacterial activity
against two bacteria, the Gram positive bacterium S. aureus
and theGramnegative bacteriumE. coli. Despite the apparent
similarities of the compounds, the preliminary experiments
showed that they present different antimicrobial activities.
Table 1: Minimum inhibitory concentrations (MICs) shown by
complexes and ligands against test bacteria.
MIC in 𝜇g/mL (mmol/L)
Staphylococcus
aureus Escherichia coli
[Cr(phen)3]
3+ 1 (0.0011) 0.25 (0.0003)
[Cr(phen)2(dppz)]
3+ 0.5 (0.0004) 0.125 (0.0001)
CrCl3⋅6 H2O No activity No activity
[Ru(phen)3]
2+
>1024 (>1.437) >1024 (>1.437)
[Ru(bpy)3]
2+
>1024 (>1.599) >1024 (>1.599)
Dipyrido[3,2-a:2󸀠,3󸀠-c]-
phenazine No activity No activity
1,10-Phenanthroline No activity No activity
2,2󸀠-Bipyridine No activity No activity
Ciprofloxacin 0.5 (0.0013) 0.125 (0.0003)
Chromium(III) complexes demonstrated antimicrobial
activity against Gram positive and Gram negative bacteria.
The Ru(II) complexes showed less activity than the Cr(III)
complexes (Table 1). The bpy, phen, dppz, and CrCl
3
⋅ 6H
2
O
(Cr3+ as free ion) show poor activity in comparison with
that of the metal complexes against the two bacterial strains.
Among all complexes of the series under test for determina-
tion of MIC (Figure 1), [Cr(phen)
2
(dppz)]3+ was found to be
the most potent. It registered MIC as shown by ciprofloxacin
against two bacterial strains.
E. coli was found to be more susceptible to
[Cr(phen)
2
(dppz)]3+ than S. aureus, with an MIC for E. coli
of 0.125𝜇g/mL and an MIC for S. aureus of 0.5 𝜇g/mL while
the MIC for E. coli was 0.25𝜇g/mL and for S. aureus 1 𝜇g/mL
for [Cr(phen)
3
]3+. Unlike those found for the ligands or Cr3+
alone, synthesizedmetal complexes of chromium(III) showed
high antimicrobial activities against E. coli and S. aureus.
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Figure 2:The fractional inhibitory concentration (FIC) index of [Cr(phen)
3
]3+ in Staphylococcus aureusATCC 29213 using the checkerboard
technique.
Table 2: Minimum inhibitory concentrations (MICs) in 𝜇g/mL and
fractional inhibitory concentration indices (FICIs) of [Cr(phen)
3
]3+
in combination with ciprofloxacin against Staphylococcus aureus
ATCC 29213∗.
Ciprofloxacin (MIC = 0.5)
[Cr(phen)
3
]
3+ (MIC = 1) MICA−C FIC
MICC−A FIC 0.033 0.066
0.5 0.5 FICIC+A = 0.566
0.25 0.25 FICIC+A = 0.316
0.125 0.125 FICIC+A = 0.191
∗MICC−A: MIC of [Cr(phen)3]
3+ in combination with ciprofloxacin.
MICA−C: MIC of ciprofloxacin in combination with [Cr(phen)3]
3+. FIC:
fractional inhibitory concentration. FICIC+A: fractional inhibitory concen-
tration index (FIC of [Cr(phen)
3
]
3+ plus FIC of ciprofloxacin).
3.2. Checkerboard Assay. When ciprofloxacin was combined
with [Cr(phen)
3
]3+ for the inhibition of S. aureus and E. coli,
an important synergistic effect was observed (Tables 2 and 3).
A notable synergism was observed in E. coli (FIC 0.032)
when the concentration of the ciprofloxacin was decreased
to 0.016 𝜇g/mL, equivalent to 15 times less than its MIC
(Table 3).When the [Cr(phen)
3
]3+ was combined with cipro-
floxacin, a surprising synergistic effect (FICIC+A = 0.096) was
observed, even when the concentration of the former was
decreased 4 times below itsMIC and of the antibiotic 31 times
below its individual MIC (Figures 2 and 3).
3.3. Time-Kill Study. When [Cr(phen)
3
]3+ was tested against
S. aureus (Figure 1) atMIC, a difference of 3 log
10
in the num-
ber of viable cells compared to the control was observed after
16 h of incubation. When this complex was assayed against
E. coli, the treatment at MIC reached differences of 3 log
10
with respect to the control after 8 h of exposure. At this time,
a complete bactericidal effect was observed.
Table 3: Minimum inhibitory concentrations (MICs) in 𝜇g/mL and
fractional inhibitory concentration indices (FICIs) of [Cr(phen)
3
]3+
in combination with ciprofloxacin against Escherichia coli ATCC
25922∗.
Ciprofloxacin (MIC = 0.25)
[Cr(phen)
3
]
3+ (MIC = 0.125) MICA−C FIC
MICC−A FIC 0.016 0.064
0.064 0.512 FICIC+A = 0.576
0.032 0.256 FICIC+A = 0.320
0.016 0.128 FICIC+A = 0.192
0.008 0.064 FICIC+A = 0.128
0.004 0.032 FICIC+A = 0.096
∗MICC−A: MIC of [Cr(phen)3]
3+ in combination with ciprofloxacin.
MICA−C: MIC of ciprofloxacin in combination with [Cr(phen)3]
3+. FIC:
fractional inhibitory concentration. FICIC+A: fractional inhibitory concen-
tration index (FIC of [Cr(phen)
3
]
3+ plus FIC of ciprofloxacin).
3.4. Determination of ROS by Chemiluminescence (CL) Assay.
Chemiluminescence assays indicated a higher degree of
oxidative stress in S. aureus ATCC 29213 when it was treated
with a combination of [Cr(phen)
3
]3+ at 1 𝜇g/mL with cipro-
floxacin at 0.5 𝜇g/mL, and the maximum value of RLU
obtained was 1.167 ± 0.016, representing an increase of 2-fold
with respect to the control without antibiotic or the complex
(Figure 4), while for the combination of [Cr(phen)
3
]3+ at
4 𝜇g/mL (concentration supra MIC) with ciprofloxacin at
0.5 𝜇g/mL, the increase in RLU was 3.9-fold with respect to
the control (data not shown).
When E. coli was treated with a combination of
[Cr(phen)
3
]3+ at 0.125𝜇g/mLwith ciprofloxacin at 0.5𝜇g/mL,
the maximum value of RLU obtained was 0.779 ± 0.040,
representing an increase of 2-fold with respect to the con-
trol (Figure 5), while for the combination with lower con-
centrations of [Cr(phen)
3
]3+ and ciprofloxacin, 0.03 and
0.06𝜇g/mL, respectively, the increase of RLU with respect to
the control was 4.8-fold.
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Figure 3: The fractional inhibitory concentration (FIC) index of [Cr(phen)
3
]3+ in Escherichia coli ATCC 25922 using the checkerboard
technique.
These results were in agreement with the level of suscep-
tibility of each strain to the combination of the complex with
the antibiotic, since S. aureus was more resistant than E. coli,
and this could have been related to less generation of ROS
occurring in the Gram positive bacteria.
4. Discussion
Despite the range of antibacterial agents currently available,
the development of new therapeutic alternatives to deal with
pathogens is of great interest for researchers and pharma-
ceutical industries. In our biological experiments, by using
chromium(III) complexes we have observed high biological
activity against Gram negative and Gram positive bacteria. It
may be concluded that the chromium(III) complexes used in
the present work inhibit the growth of bacteria to a greater
extent compared to ciprofloxacin, the reference drug. This
fact contrasts with what was found for others chromium(III)
complexes containing amino acids as a ligands against Gram
negative and Gram positive bacteria, where the MIC values
of the complexes are higher than the values for the standard
antibiotic [26].
The efficiencies of the ligands and the chromium(III)
complexes have been tested against Gram positive, S. aureus,
and Gram negative, E. coli, microorganisms. It is not
clear why the other compounds tested, [Ru(phen)
3
]2+ and
[Ru(bpy)
3
]2+, did not show antimicrobial activity at the
concentration range used.The results are presented inTable 1.
The antimicrobial activity of CrCl
3
⋅ 6H
2
O has also been
investigated. It has been found that CrCl
3
⋅ 6H
2
O does not
exhibit antimicrobial activity at the concentration range used
to assay the activity of the complexes in this work.
In general, for metal complexes showing antimicrobial
activity, the following five principal factors should be consid-
ered: (i) the chelate effect, that is, ligands that are bound to
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Figure 4: ROS generation in Staphylococcus aureus ATCC 29213
incubated with [Cr(phen)
3
]3+ at MIC concentration determined
by chemiluminescence assay. Control (◻); treated with 1 𝜇g/mL
[Cr(phen)
3
]3+ and 0.125 𝜇g/mL ciprofloxacin (◼); treated with
1 𝜇g/mL [Cr(phen)
3
]3+ and 0.25 𝜇g/mL ciprofloxacin (Δ); treated
with 1 𝜇g/mL [Cr(phen)
3
]3+ and 0.5 𝜇g/mL ciprofloxacin (󳵳);
treated with 1𝜇g/mL [Cr(phen)
3
]3+ and 1 𝜇g/mL ciprofloxacin (∘);
treated with 1 𝜇g/mL [Cr(phen)
3
]3+ and 2𝜇g/mL ciprofloxacin (∙);
treated with 1𝜇g/mL [Cr(phen)
3
]3+ and 4𝜇g/mL ciprofloxacin (◊).
metal ions in a bidentate fashion, such as the nitrogen-donor
ligands phen and bpy, show higher antimicrobial efficiency
towards complexes with unidentate nitrogen-donor ligands,
for example, pyridine; (ii) the nature of the ligands; (iii)
the total charge of the complex, generally the antimicrobial
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Figure 5: ROS generation in Escherichia coli ATCC 25922 incu-
bated with [Cr(phen)
3
]3+ at MIC concentration determined by
chemiluminescence assay. Control (∘); treated with 0.125 𝜇g/mL
[Cr(phen)
3
]3+ and 0.06 𝜇g/mL ciprofloxacin (∙); treated with
0.125 𝜇g/mL [Cr(phen)
3
]3+ and 0.125 𝜇g/mL ciprofloxacin (◻);
treated with 0.125 𝜇g/mL [Cr(phen)
3
]3+ and 0.5𝜇g/mL ciproflox-
acin (󳵳); treated with 0.125𝜇g/mL [Cr(phen)
3
]3+ and 1 𝜇g/mL
ciprofloxacin (Δ); treated with 0.125 𝜇g/mL [Cr(phen)
3
]3+ and
2𝜇g/mL ciprofloxacin (∗).
efficiency decreases in the order cationic > neutral > anionic
complex, (iv) the nature of the ion neutralizing the ionic
complex; (v) the nuclearity of themetal center in the complex;
dinuclear centers are usually more active than mononuclear
ones [36]. The first two of the five above-mentioned factors
are present in our compounds, that is, the chelate effect pro-
vided by nitrogen-donor ligands (phen, bpy, and dppz) and
the nature of the ligands.
It is evident (Table 1) that the antimicrobial activity of the
chromium(III) complexes against S. aureus and E. coli is bet-
ter than that of the ligands. A similar behavior was observed
by Efthimiadou et al. for copper(II) complexes with nitrogen-
donor heterocyclic ligands against P. aeruginosa, S. aureus,
and E. coli [37]. Considering the nature of the nitrogen-
donor heterocyclic ligand in the chromium(III) complexes,
our results suggest that the inhibition of the growth of
microorganisms increases in the order dppz > phen, where
the [Cr(phen)
2
(dppz)]3+ complex was found to be the most
potent.
Finally, when ciprofloxacin was combined with
[Cr(phen)
3
]3+ for the inhibition of S. aureus and E. coli, an
important synergistic effect was observed (Tables 2 and 3).
We found that S. aureuswasmore resistant than E. coli to gen-
eration of ROS by both antimicrobial agents combined, cipro-
floxacin and [Cr(phen)
3
]3+, this would be related to less
increase of ROS in Gram positive bacteria (Figures 4 and 5).
The present study provides the first evidence of
antimicrobial activity of the synthetic metallomolecules
[Cr(phen)
3
]3+ and [Cr(phen)
2
(dppz)]3+. We have synthe-
sized and characterized various 𝛼-diimine chromium(III)
complexes with different ligands, and similar compounds of
copper(II) have been recently synthesized, some of which
may show a higher degree of antimicrobial activity [38].
Therefore, future studies will be directed to the antimicrobial
activity of the newly synthesized complexes, as well as the
activity of metal complexes on drug-resistant pathogenic
bacteria.
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